Curcumin, a natural pigment for yellow color that originates from turmeric, is a diarylheptanoid widely studied for its antiinflammatory, antiangiogenic, antioxidant, and anticancer effects on cells. In placental diseases, including preeclampsia and preterm birth, curcumin reduces proinflammatory cytokines. Even though curcumin is regarded as a novel chemotherapeutic agent with strong apoptotic effects based on phenolic structure, little is known about its functional effects on choriocarcinoma. Therefore, in the present study, we investigated the chemotherapeutic effects of curcumin on choriocarcinoma cells (JAR and JEG3), which are valuable placental models. The results showed that curcumin decreased viability of choriocarcinoma cells in a dose-dependent manner. In addition, proliferative and migratory characteristics of JAR and JEG3 cells were inhibited by curcumin treatment and curcumin-induced apoptotic effects, which were assessed using TUNEL and annexin V/propidium iodide staining. Moreover, curcumin increased depolarization of the mitochondrial membrane based on JC-1 staining and changed expression of apoptotic proteins. Phosphorylation of mitogen-activated protein kinases (MAPK) responsible for regulation of anticancer effects of curcumin were examined for dose-and timedependent effects. The ERK1/2 and SAPK/JNK and their downstream molecules including P90RSK and c-Jun, respectively, were activated by curcumin. Moreover, pharmacological inhibitors of ERK1/2 (U0126) and SAPK/JNK (SP600125) suppressed ERK1/2 and SAPK/JNK activation respectively, and blockage of P38 MAPK by its inhibitor (SB203580) had a synergistic effect with curcumin. These results indicate that curcumin acts as a novel chemotherapeutic agent on human placental choriocarcinoma cells via activation of ERK1/2 and SAPK/JNK signal transduction cascades.
INTRODUCTION
Choriocarcinoma is involved in gestational trophoblastic neoplasia usually arising from villous trophoblast hydatidiform mole formation resulting in a botryoid structure due to abnormal proliferation of trophoblastic tissue, and it occurs in 1 of 40 000 pregnancies [1] [2] [3] . This type of tumor is malignant because of its invasive, relapsing characteristics [4] as well as metastasis to the brain [5] , lung [6] , and liver [7] . For diagnosis and monitoring of therapeutic effects on choriocarcinoma, bhuman chorionic gonadotropin (b-hCG) is used predominantly as a serum marker, and elevated levels of b-hCG indicate advanced stages, increasing the incidence of metastatic sites, according to Federation of Gynecology and Obstetrics guidelines [8] . Although most premalignant hydatidiform moles can be removed by suction curettage, malignant forms or recurrent choriocarcinoma require systemic chemotherapy. In particular, etoposide combined with a platinum-based agent is the chemotherapeutic strategy mainly used with surgical excision of tumors, and results in approximately a 90% survival rate in women diagnosed with choriocarcinoma. However, when the diagnosis is made in the advanced stage of the disease it is difficult to manage and overcome completely the adverse effects of choriocarcinoma [9, 10] . Moreover, because of differentiation of malignant cells derived from abnormal trophoblast tissue into placenta or fetus, successful placentation and embryogenesis is not achieved in women who suffer from choriocarcinoma [11, 12] . Therefore, it is important to develop new therapeutics that exclude side effects that prevent establishment of a successful pregnancy. Emerging epidemiological, clinical, and in vivo and in vitro studies suggest that natural dietary compounds from plants, fruits, and vegetables play crucial roles in the prevention of cardiovascular diseases, diabetes, neurodegenerative diseases, and cancers based on their multiple biological activities. Polyphenols, which consist mostly of phenolic acids, flavonoids, stilbenes, and lignans, represent a ubiquitous group of natural compounds also called phytochemicals. The polyphenol-rich diet has recently been demonstrated to have chemopreventive properties, and it supports efforts to develop natural agents to arrest carcinogenesis in its early stages in cancer patients [13] . Chemopreventive effects of polyphenols affect molecular mechanisms that impede initiation, promotion, and progression of cancers by regulating intracellular signaling molecules [14, 15] . In addition, polyphenolic compounds induce apoptosis in cancer cells via modulation of proapoptotic and antiapoptotic factors and caspases associated with apoptotic pathways [16, 17] . However, because of different mechanisms of action for each of the polyphenolic compounds, details of genetic and epigenetic signaling mechanisms are unclear in cancer.
One major polyphenol is curcumin, a diketone compound isolated from the rhizomes of the plant Curcuma longa. Curcumin has anti-inflammatory, antiangiogenic, anticancer, antimetastatic, and antioxidant effects [18] . The cancerpreventive and therapeutic potential of curcumin has been reported for breast cancer, gastrointestinal cancer, head and neck cancers, gynecologic cancers, lung cancers, bone cancer, brain cancer, prostate cancer, skin cancer, and liver cancer based on in vivo and in vitro studies [19, 20] . For example, curcumin induces apoptosis in ovarian carcinoma by activation of p38 mitogen-activated protein kinase (MAPK) and downregulation of Bcl-2 expression and AKT signaling [21] . And it suppresses the growth of androgen-independent prostate cancer cells through mediating extracellular signal-regulated kinase 1/ 2 (ERK1/2) and stress-activated protein kinase/c-Jun Nterminal kinases (SAPK/JNK) signal transduction, which inhibits NF-jB subunit p65 [22] . In addition, antiproliferative effects of curcumin on breast cancer cells are induced by downregulation of enhancer of zeste homolog 2 (EZH2) mediated through the MAPK signaling pathway [23] . However, there is little known about anticancer effects of curcumin on human placental choriocarcinoma cells.
In the present study, we investigated the use of curcumin as an anticancer agent in choriocarcinoma cells (JAR and JEG3). We determined the effects of curcumin on proliferation, migration, and apoptosis of choriocarcinoma cells, and investigated the molecular mechanisms whereby curcumin decreased carcinogenic properties and induced apoptosis of JAR and JEG3 cells using pharmacological inhibitors. Results of the present study provide evidence that curcumin possesses strong chemopreventive effects against development of choriocarcinoma cells and that it may be a valuable therapeutic agent for prevention of progression of placental choriocarcinoma and for treatment of patients with gestational trophoblastic neoplasias.
MATERIALS AND METHODS

Chemicals
Curcumin was purchased from HWI ANALYTIK GmbH (Cat. No. C7727). The SB203580 (a P38 MAPK inhibitor), SP600125 (a JNK MAPK inhibitor), and U0126 (an ERK1/2 MAPK inhibitor) were from Enzo Life Science. (Ser  73 ) and total ERK1/2, RSK1/RSK2/RSK3, JNK, c-Jun, Bak, Bax, Bad, Bcl-2, caspase-9, and Bcl-xL were purchased from Cell Signaling Technology. Anti-TUBA antibody was purchased from Santa Cruz Biotechnology.
Cell Culture
JAR and JEG3 cells, which were tested and authenticated, were purchased from the American Type Culture Collection in January 2015 and maintained in RPMI-1640 with 2.05 mM L-glutamine (Cat. No. SH30027.01; HyClone) for JAR cells and MEM (Cat. No. 11095-080; Gibco) for JEG3 cells with 10% fetal bovine serum at 378C in an incubator with an atmosphere of 5% CO 2 . For experiments, monolayer cultures of JAR and JEG3 cells were grown in culture medium to 70% confluence in 100-mm tissue culture dishes. Cells were serum starved for 24 h and then treated with curcumin alone and with inhibitors of cell signaling pathways.
Proliferation Assay
Proliferation assays were conducted to identify cytotoxicity of curcumin in JAR and JEG3 cells using the Cell Proliferation ELISA, bromodeoxyuridine (BrdU) kit (Cat. No. 11647229001; Roche) according to the manufacturer's recommendations. Briefly, both JAR and JEG3 cells (3 3 10 3 cells per 100 ll/ well) were seeded in a 96-well plate, and then incubated for 24 h in serum-free medium. The cells were then treated with curcumin and various treatments in a final volume of 100 ll/well. To compensate for total volume of vehicle in each well, we added vehicle up to the highest treatment dose for each assay. After 48 h of incubation, 10 lM BrdU was added to the cell culture and the cells were incubated for an additional 2 h at 378C. After labeling of cells with BrdU, the fixed cells were incubated with anti-BrdU-peroxidase (POD) working solution for 90 min. The anti-BrdU-POD binds to BrdU incorporated in newly synthesized cellular DNA, and these immune complexes were detected by the reaction to TMB substrate. The reacted products were quantified by measuring the absorbance at 370 nm and 492 nm using an ELISA reader.
Transwell Migration Assay
JAR and JEG3 cells (1 3 10 5 cells per 100 ll serum-free media) were seeded on 8-lm-pore Transwell inserts (Cat. No. 3422; Corning, Inc.) and treatments were added to each well to investigate migratory effects of curcumin on choriocarcinoma cells. After 12 h, the inserts were removed from the chamber. For evaluation of cells that migrated onto the lower surface, inserts were fixed in methanol for 10 min. The Transwell membranes were then air dried and stained using hematoxylin (Cat. No. HHS32; Sigma-Aldrich) for 30 min. The insert membranes were washed gently several times with tap water to remove excess stain. The cells on the upper side of the inserts were removed with a cotton swab. The Transwell membranes were removed and placed on a glass slide with the side containing cells facing up, and the slide was covered with Permount solution. Migrated cells were counted in five nonoverlapping locations, which covered approximately 70% of the insert membrane growth area, using a DM3000 microscope (Leica). The entire experiment was repeated at least three times.
Immunofluorescence Microscopy
The effects of curcumin on the expression of proliferating cell nuclear antigen (PCNA) were determined by immunofluorescence microscopy. JAR and JEG3 cells were probed with mouse antihuman monoclonal PCNA antibody (Cat. No. sc-56; Santa Cruz Biotechnology) at a final dilution of 1:100 (2 lg/ml). They were then incubated with goat antimouse IgG Alexa 488 (Cat. No. A-11001; Invitrogen) at a 1:200 dilution for 1 h at room temperature. The cells were then washed using 0.1% bovine serum albumin (BSA) in PBS and overlaid with 4 0 ,6-diamidino-2-phenylindole (DAPI; Cat. No. D8417; SigmaAldrich, Inc.). For each primary antibody, images were captured using a LSM710 confocal microscope (Carl Zeiss).
TUNEL Assay
The cells (3 3 10 4 cells per 300 ll) were seeded on confocal dishes (Cat. No. 100350; SPL Life Science) and then incubated for 24 h in serum-free medium. Cells were then treated with curcumin at a concentration of 50 lM for 48 h at 378C in a CO 2 incubator. After incubation, the cells were air dried and fixed with 4% paraformaldehyde in PBS for 1 h at room temperature. The cells were rinsed with PBS briefly and permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice. Then, the cells were subjected to a TUNEL staining mixture using the In Situ Cell Death Detection kit, TMR red (Roche) for 1 h at 378C in the dark. Cells then were washed with PBS and overlaid with DAPI. Fluorescence was detected using a LSM710 confocal microscope fitted with a digital microscope AxioCam camera with Zen2009 software.
Annexin V and Propidium Iodide Staining
Apoptosis of choriocarcinoma cells induced by curcumin was analyzed using the FITC Annexin V Apoptosis Detection Kit I (BD Biosciences). Both JAR and JEG3 cells (5 3 10 5 cells) were seeded on six-well plates and incubated for 24 h in serum-free medium when cells were at 70% confluency. Then, cells were treated with curcumin in a dose-dependent manner for 48 h at 378C in a CO 2 incubator. Supernatants were removed from culture dishes and adherent cells detached with trypsin-EDTA. The cells were collected by centrifugation, washed with PBS, and resuspended using 13 binding buffer at 1 3 10 6 cells/ml. Then, 100 ml of the cell suspension (1 3 10 6 cells) was transferred to a 5-ml culture tube and incubated with 5 ll FITC Annexin V and 5 ll propidium iodide (PI) for 15 min at room temperature in the dark. Finally, 400 ml of 13 binding buffer was added in a 5-ml culture tube. Fluorescence intensity was analyzed using a FACSCalibur (BD Biosciences).
LIM ET AL.
JC-1 Mitochondrial Membrane Potential Assay
Changes in mitochondrial membrane potential (MMP) were analyzed using a mitochondria staining kit (Cat. No. CS0390; Sigma-Aldrich). Both JAR and JEG3 cells (5 3 10 5 cells) were seeded in six-well plates and incubated for 24 h in serum-free medium to 70% confluency. Then, cells were treated with curcumin in a dose-dependent manner for 48 h at 378C in a CO 2 incubator. Supernatants were removed from culture dishes and adherent cells detached with trypsin-EDTA. The cells were collected by centrifugation, resuspended using staining solution including 2003 JC-1 at 13 staining buffer, and incubated at 378C in a CO 2 incubator for 20 min. The stained cells were collected by centrifugation and washed once with 13 JC-1 staining buffer.
After a washing, the cell suspension was centrifuged once more and then the cells were resuspended in 1 ml staining buffer. Fluorescence intensity was analyzed using a FACSCalibur.
Protein Extraction
JAR and JEG3 cells were cultured in 100-mm dishes for 24 h in serum-free medium. Both JAR and JEG3 cells were treated with curcumin (0-50 lM) for 2 h. Thereafter, the medium was removed and the cells rinsed rapidly twice with ice-cold PBS containing calcium and magnesium. The cells were then lysed for 30 min at 48C in 150 ll of IP lysis buffer consisting of 1% Triton X-100, 0.5% NP-40, 150 mM NaCl, 100 mM Tris-HCl (pH 7.6), 1 mM EDTA, 1 mM ethylene glycol tetra-acetic acid, 0.2 mM Na 3 VO 4 , and cOmplete EDTA-free protease inhibitor cocktail (Roche). Cell lysates were centrifuged (21 000 3 g for 15 min at 48C). Finally, supernatant was transferred to a clean 1.5-ml tube and stored at À808C until analyzed.
Cytoplasmic and Nuclear Protein Extraction
Cytoplasmic and nuclear fractions were analyzed using NE-PER nuclear and cytoplasmic extraction reagents (Cat. No. 78833; Thermo). Both JAR and JEG3 cells were harvested with trypsin-EDTA and then centrifuged at 500 3 g for 5 min. Both cell lines were washed by suspending the cell pellet in PBS and transferring 1 3 10 6 cells to a 1.5-ml microcentrifuge tube. Then, the cells were harvested by centrifugation at 500 3 g for 3 min. The supernatant was removed and the pellet was left to dry. The pellet was next suspended in ice-cold CER I and incubated on ice for 10 min. After that, ice-cold CER II solution was added to the tube, mixed well, and incubated in the tube on ice for 1 min. The tube was vortexed briefly and centrifuged at 16 000 3 g for 5 min. Supernatant (cytoplasmic extract) was immediately transferred to a clean, prechilled tube and stored at À808C until analyzed. The remaining pellets containing nuclei were suspended in ice-cold NER solution and the tube vortexed for 15 sec and incubated on ice for 40 min. Then, the tube was centrifuged at 16 000 3 g for 10 min. Supernatant (nuclear extract) was immediately transferred to a clean prechilled tube and stored at À808C until analyzed.
Western Blot Analysis
Concentrations of protein in whole-cell extracts were determined using the Bradford protein assay (Bio-Rad) with BSA as the standard. Proteins were denatured, separated using SDS-PAGE, and transferred to nitrocellulose. Blots were developed using enhanced chemiluminescence detection (SuperSignal West Pico; Pierce) and quantified by measuring the intensity of light emitted from correctly sized bands under ultraviolet light using a ChemiDoc EQ system and Quantity One software (Bio-Rad). Immunoreactive proteins were detected using goat antirabbit polyclonal antibodies against phosphoproteins and total proteins at a 1:1000 dilution after being separated on a 10% SDS/PAGE gel. As a loading control, total proteins were used to normalize results for detection of proteins by Western blotting. All antibodies were from Cell Signaling Technology. Multiple exposures of each Western blot were performed to ensure linearity of chemiluminescent signals.
Statistical Analysis
Data from proliferation and migration assays were subjected to ANOVA according to the general linear model (PROC-GLM) of the SAS program (SAS Institute) to determine whether there were significant differential effects of treatments on choriocarcinoma cells. Differences with a probability value of P , 0.05 were considered statistically significant. Data are presented as mean 6 SEM unless otherwise stated.
RESULTS
Curcumin Suppresses Proliferation and Migration of Choriocarcinoma Cells
To investigate the effects of curcumin on choriocarcinoma cells, we performed a cell viability analysis using JAR and JEG3 cells in a dose-dependent manner (0, 5, 10, 20, 50, and 100 lM). The viability of both cells decreased (P , 0.001) in a dose-dependent manner in response to curcumin (Fig. 1A) . At 50 lM curcumin, cell viability was less than 50% for JAR cells (P , 0.001) and 51% for JEG3 cells compared to control cells (P , 0.01). Consistent with these results, we compared the CURCUMIN INDUCES APOPTOSIS OF CHORIOCARCINOMA expression of PCNA, which is a DNA clamp essential for replication and a biomarker for cell proliferation, between curcumin-treated and nontreated choriocarcinoma cells using immunofluorescence analyses. Nontreated cells expressed abundant PCNA (green fluorescence) in the nucleus, but the expression of PCNA was rarely detected in JAR and JEG3 cells treated with 50 lM curcumin (Fig. 1B) . Next, we estimated the inhibitory effect of curcumin on migration of choriocarcinoma cells using a Transwell migration assay. Curcumin (50 lM) decreased migration of both JAR and JEG3 cells compared to control cells (P , 0.001; Fig. 1C ). These results indicate that curcumin has antiproliferative and antimigratory effects on choriocarcinoma cells.
Curcumin Induces Apoptosis in Choriocarcinoma Cells
To determine whether curcumin induces apoptosis of JAR and JEG3 cells, we analyzed cell death using the TUNEL reaction. Although nontreated choriocarcinoma cells did not exhibit red fluorescent emission as an indicator of DNA fragmentation, curcumin-treated JAR and JEG3 cells contained fragmented DNA predominantly in their nuclei ( Fig. 2A) . Moreover, we analyzed annexin V fluorescein isothiocyanate and PI staining using flow cytometry. In a dose-dependent manner, the main population of JAR and JEG3 cells treated with curcumin moved toward the upper right quadrant, indicating progression of apoptosis. Specifically, treatment of curcumin at the highest dose, 50 lM, resulted in a 9.18-fold increase in apoptotic JAR cells compared to nontreated cells and a 1.99-fold increase in apoptotic JEG3 cells (Fig. 2B) . These results indicate that curcumin induced apoptosis in the choriocarcinoma cells.
Curcumin Affects the Apoptotic Pathway Mediated by Mitochondria
MMP is mainly used as an index that reflects the health status of the mitochondria. Depolarization of mitochondria was visualized by JC-1 dye, which aggregates and emits red fluorescence for viable mitochondria while the monomer emits green fluorescence indicative of loss of MMP. The results indicated that mitochondria in JAR and JEG3 cells did not lose MMP when treated with 0, 10, or 20 lM curcumin, whereas there was a loss of MMP in both cell lines when treated with 50 lM curcumin (Fig. 3A) . The MMP for JAR and JEG3 cells was decreased 309% and 445%, respectively, in response to curcumin (50 lM). Further, we analyzed proapoptotic and antiapoptotic proteins responsible for loss of MMP (Fig. 3B) . In a dose-dependent manner, Bad expression increased in both JAR and JEG3 cells, whereas Bcl-2 expression decreased in JAR cells, but not in JEG3 cells treated with 50 lM curcumin. Bak and Bax proteins increased in curcumin-treated compared to control JAR cells; however, Bak protein decreased in JEG3 cells in a dose-response manner in response to curcumin. Moreover, curcumin resulted in activation of caspase-9, as indicated by increases in the cleaved form of caspase-9 in both JAR and JEG3 cells. The loss of MMP and the changes in antiapoptotic and proapoptotic proteins suggest that curcumin influences the intrinsic apoptotic pathway in choriocarcinoma cells.
ERK1/2 and SAPK/JNK MAPKs Signaling Pathways Are Activated by Curcumin
Next, we investigated signaling molecules potentially involved in the effects of curcumin on choriocarcinoma cells using Western blot analyses. Significant increases in phos- Immunoblots were captured to calculate the normalized values, which are presented in the graph as estimates of the abundance of phosphorylated proteins relative to total proteins. The asterisks indicate an effect of treatment (*P , 0.05, **P , 0.01, and ***P , 0.001).
CURCUMIN INDUCES APOPTOSIS OF CHORIOCARCINOMA phorylated ERK1/2 and JNK proteins were detected in a dosedependent manner for curcumin-treated JAR and JEG3 cells (Fig. 4, A and C) . We also examined the abundance of proteins downstream of ERK1/2 and JNK, including P90RSK and cJun, respectively. Phosphorylated P90RSK and c-Jun were increased in a dose-and time-dependent manner by curcumin in both choriocarcinoma cell lines (Fig. 4, B and D) . Phosphorylated ERK1/2 and P90RSK were increased between 7.5 and 120 min after treatment of the JAR and JEG3 cells with curcumin (Fig. 5, A and B) . In addition, the phosphorylation of JNK was predominantly between 60 and 120 min after curcumin treatment (Fig. 5C) . Consistent with expression of JNK protein, the phosphorylated form of c-Jun protein was increased in a time-dependent manner in the JAR and JEG3 cells (Fig. 5D) . Further, nuclear-specific expression of c-Jun protein was increased by curcumin treatment in the JAR and JEG3 cells, whereas alpha-tubulin (TUBA) protein was specific to the cytoplasm (Supplemental Fig. S1 , available online at www.biolreprod.org). These results suggest that ERK1/2 and JNK MAPK cell signaling in response to curcumin has anticancer effects.
Blockage of MAPK Signaling with Curcumin Influences Progression of Choriocarcinoma Cells
To further establish the relationship between MAPK signaling and apoptosis of choriocarcinoma cells, we determined viability of curcumin-treated JAR and JEG3 cells in the presence of inhibitors including SB203580 (a p38 MAPK inhibitor), SP600125 (a JNK MAPK inhibitor), and U0126 (an ERK1/2 MAPK inhibitor). The dosage of each pharmacological inhibitor was based on results from previous studies [24, 25] . The viability of JAR cells treated with curcumin was synergistically suppressed by SB203580, SP600125, and U0126 as compared to treatment with curcumin or each of the inhibitors alone (Fig. 6A) . For JEG3 cells treated with curcumin as well as SB203580, SP600125, and U0126, there was only a slight inhibition of cell viability compared to effects of treatment with each inhibitor separately (Fig. 6B) . Consistent with these results, we determined expression of target proteins in response to inhibitors and curcumin as illustrated in Figure 7 . The activation of phosphorylated ERK1/ 2 by curcumin was completely blocked by U0126 in JAR and JEG3 cells (Fig. 7A) , and also reduced by SB203580 and Immunoblots were captured to calculate the normalized values presented in the graph, which indicate estimates of the abundance of phosphorylated proteins relative to total proteins. The asterisks indicate an effect of treatment (*P , 0.05, **P , 0.01, and ***P , 0.001).
SP600125 in JAR cells. Phosphorylated P90RSK, a downstream signaling molecule of ERK1/2, was increased in response to curcumin, but its expression was decreased by U0126 in both choriocarcinoma cell lines (Fig. 7B) . In addition, the abundant phosphorylation of JNK in response to curcumin was significantly reduced by SP600125 and U0126 and slightly increased by SB203580 (Fig. 7C) . For JNK expression, the remarkable increase in phosphorylated c-Jun in response to curcumin in control cells was decreased by SP600125 and U0126, but slightly increased by SB203580 (Fig. 7D) in the JAR and JEG3 cells. These results revealed that inhibition of the MAPK signaling pathways with curcumin decreases viability of the choriocarcinoma cell lines.
DISCUSSION
Results of the present study support our hypothesis that curcumin exerts anticancer effects on choriocarcinoma cells by inducing apoptosis and regulating cell proliferation and migration. In addition, we present evidence that the mechanism(s) responsible for the apoptotic effects of curcumin are mediated via the ERK1/2 and JNK MAPK pathways in both choriocarcinoma cell lines. Further, our results reveal that the intrinsic apoptotic pathway is involved in curcumin-induced programmed cell death mediated by mitochondria (Fig. 8) .
Plant-derived phytochemicals are appealing as new natural anticancer agents. Among them, curcumin is well known for its medicinal properties in Indian and Chinese medicine [18] . Its anticancer effects, among other numerous therapeutic effects, were reported mostly for breast cancer, prostate cancer, and colon cancer [26] [27] [28] , but the effects on choriocarcinoma cells had not been studied. The molecular targets of curcumin are diverse depending on cancer type, but effects are mediated primarily via the ERK1/2 and JNK MAPK pathways. As an anti-inflammatory agent, curcumin suppresses activation of ERK1/2 and JNK signaling pathways against Jurkat cells treated with phorbol 12-myristate 13-acetate and ionomycin and vascular smooth muscle cells treated with lipopolysaccharide [29, 30] . However, ERK1/2 and JNK signaling pathways are activated for anticancer effects of drugs against lung cancer, prostate cancer, and leukemia [31] [32] [33] . Downstream signaling molecules of ERK1/2 and JNK MAPK such as Jun-D, c-Jun, and c-Fos normally form dimers with each other to form the AP-1 transcription factor complex. AP-1 is involved in diverse biological processes, including normal cell proliferation/ differentiation and inflammation [34] . Curcumin was suggested to abrogate activation of AP-1 to inhibit tumor growth [35] , but others reported that AP-1 was activated to promote apoptosis of tumor cells [31] [32] [33] .
Consistent with results of previous studies, we found that curcumin inhibits proliferation and migration of JAR and JEG3 cells and also induces apoptosis of those cells. As illustrated in Figure 1 , curcumin decreased survival rates, proliferation, and migration of JAR and JEG3 cells. In addition, fragmented DNA, visualized by TUNEL reaction (red fluorescence), was abundant in the curcumin-treated JAR and JEG3 cells as compared to nontreated control cells. Moreover, flow cytometry analyses after staining of cells with annexin V and PI showed apoptotic progression of both choriocarcinoma cell lines in a dose-dependent manner. These results demonstrate that curcumin has anticancer effects on choriocarcinoma cells.
Mitochondria play an important role in inducing apoptosis through various stimuli. In the present study, we found that curcumin-induced apoptotic pathways in gestational trophoblastic neoplasia are affected via mitochondrial-mediated pathways. MMP was decreased in choriocarcinoma cells treated with 50 lM curcumin compared to nontreated cells. Disruption of MMP commonly induces apoptosis, leading to secretion of cytochrome c and reduction of ATP synthesis [36, 37] . Curcumin is known as a stimulator of a loss of MMP for induction of apoptosis in lung adenocarcinoma [38] and hepatocellular carcinoma [39] . In accordance with those results, the antiapoptotic proteins (Bcl-2 and Bcl-xL) were decreased in abundance only in the JAR cells, whereas the proapoptotic proteins, including Bad, Bak, Bax, and cleaved caspase-9, were mostly increased in a dose-dependent manner in response to curcumin. Antiapoptotic proteins inhibit release of cytochrome c via generation of heterodimer complexes with proapoptotic proteins that activates release of apoptotic signaling molecules from mitochondria to the cytosol [40] . Therefore, our results provide clear evidence that curcumin suppresses constitutive levels of MMP in choriocarcinoma cells, inhibits Bcl-2 and Bcl-xL, activates caspase-9, which is required for apoptosis.
Curcumin induces apoptosis in a variety of cancers by regulating different signaling pathways. In the present study, and pharmacological inhibitors including SB203580 (20 lM), SP600125 (10 lM), or U0126 (10 lM) or their combinations for 48 h. Cell numbers were estimated using the cell proliferation assay, and data are expressed as percentages relative to nontreated control cells (100%). All quantitative data are presented as the least square methods (LSM) with overall SEM. Asterisks indicate significant differences compared to nontreated control (*P , 0.05, **P , 0.01, and ***P , 0.001).
CURCUMIN INDUCES APOPTOSIS OF CHORIOCARCINOMA ERK1/2, JNK, and their downstream signaling proteins were increased by curcumin in a dose-and time-dependent manner in choriocarcinoma cells. Recent reports indicate that activation of AP-1 is responsible for the ability of curcumin to induce apoptosis in cancers, and that this effect is mediated by activating ERK1/2 and JNK signaling pathways, including Jun families and c-Fos [31] [32] [33] . Our results support previous results showing that P90RSK and c-Jun are activated with similar tendencies to signaling molecules for ERK1/2 and JNK, respectively, except for changes in total c-Jun protein. Total cJun protein was newly synthesized in 2 h, independent of phosphorylation. This fast change in expression of c-Jun also occurs in many cases as follows: acetaminophen-induced acute liver injury and insulin-like growth factor 1 (IGF1)-treated human colon cancer cells [41, 42] . These results suggest that activation of ERK1/2 and JNK signaling pathways mediates curcumin-induced apoptosis, and that it may be induced by AP-1, which forms as a c-Jun and c-Fos dimer.
In order to validate our results regarding the roles of ERK1/ 2 MAPK, JNK MAPK, and P38 MAPK, pharmacological inhibitors for MAPK signaling were used in conjunction with curcumin to treat choriocarcinoma cells. Therefore, we used inhibitors for ERK1/2 MAPK (U0126), JNK MAPK (SP600125), and P38 MAPK (SB203580) with curcumin, which decreased survival of JAR cells as compared with curcumin alone or with effects of the inhibitor alone. In addition, these combinations also reduced proliferation and migration of JEG3 cells more than the inhibitor alone. These results indicate that blockage of ERK1/2, JNK, and P38 MAPK pathways with curcumin has synergistic antiproliferative effects on choriocarcinoma cells. Consistent with these results, immunoblot analyses revealed that the phosphorylation of ERK1/2 and JNK MAPK was suppressed by their respective pharmacological inhibitors. Interestingly, inhibition of P38 MAPK signaling slightly increased JNK and c-Jun phosphorylation in choriocarcinoma cells, as illustrated in Figure 6 , C and D. P38 MAPK is known to participate in cell proliferation and apoptosis, and also to regulate AP-1 transcription. Specifically, P38 MAPK cannot activate AP-1 directly, but it regulates transcription of Jun and Fos by activating the ETS domain-containing protein (Elk1), transcription factor 2 (ATF2), and CCAAT/enhancer binding protein (C/EBP) [34, 43] . These results revealed that inhibition of P38 MAPK signaling may affect transcription of AP-1 by activating c-Jun to induce apoptotic events.
In summary, results of the present study indicate two important findings with respect to cancer therapy. First, curcumin is a novel therapeutic agent for choriocarcinoma treatment. Choriocarcinomas originate in placental trophoblasts, and our results suggest that, in pregnant women, curcumin therapy may be effective without adversely impacting either placental maintenance or fetal development [11] . Although choriocarcinomas are sensitive to chemotherapy, they often reoccur in subsequent pregnancies and are often accompanied by metastases, making their clinical management much more difficult [9] . As a result, new therapeutic agents are needed. Our results indicate that curcumin is an attractive candidate with synergistic effects. ERK1/2 and JNK signal transduction pathways are targets of curcumin in carcinomas arising from trophoblasts. In particular, curcumin activates cJun as a proapoptotic factor. Our results provide insights into mechanisms of action of curcumin as a novel therapeutic agent.
